UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________________

FORM 8-K

CURRENT REPORT

Pursuant to ~~Section 13 or 15(d) of~~ the Securities Exchange Act of ~~1934~~1933

Date of Report ( Date of earliest event reported )

~~September~~March 127, ~~2015~~ 2024 (~~August~~March 2726, ~~2015~~2024)

THC FARMACEUTICALS, INC.

formerly, City Media, Inc.

(Exact name of registrant as specified in its charter)

~~UTAH~~COLORADO

(State or other jurisdiction of incorporation)

000-54754

(Commission File No.)

~~7170~~1000 E.Newbury ~~McDonald~~Road ~~Dr.,~~ Suite 3290B

~~Scottsdale~~Thousand Oaks, ~~Arizona 85253~~CA., 91320

(Address of principal executive offices and Zip Code )

~~N/A~~1-323-420-8583

(Former Address of principal executive offices and Zip Code if change since last report)

(480) 725-9060

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~ITEM~~[ ~~5.02~~] ~~DEPARTURE~~Pre-commencement OFcommunications ~~DIRECTORS~~pursuant ORto ~~CERTAIN~~Rule ~~OFFICERS;~~14d-2(b) ~~ELECTION~~under OFthe ~~DIRECTORS;~~Exchange ~~APPOINTMENT~~Act OF(17 ~~CERTAIN~~CFR ~~OFFICERS;~~240.14d-2(b)) ~~COMPENSATORY~~[ ] ~~ARRANGEMENTS~~Pre-commencement OFcommunications ~~CERTAIN~~pursuant ~~OFFICERS~~to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

OnSecurities ~~August~~registered ~~27,~~pursuant ~~2015,~~to ~~Jon~~Section ~~McGee~~12(b) ~~resigned as an officer and director~~ of the ~~Company. Mr. McGee did not have disagreement with us on any matter relating to operations, policies, or practices.~~Act:

~~SIGNATURES~~Title of each class Trading Symbol(s) Name of each exchange on which registered Common CBDG OTC Markets

~~Pursuant~~ITEM ~~to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized~~8.01OTHER EVENTS

~~Dated~~On ~~this~~March ~~1st~~26 ~~day~~2024 Bret Bogue and Apothecary Genetics, (The Sellers) developers and owners of ~~September~~the rights to products known as Apothecary Genetics (“Apothecary Genetics” or the “Products”) agreed to sell those rights to THC Farmaceuticals, ~~2015~~Inc. These products include but are not limited to the approximately half-a-dozen award winning strains of herbal plants and medicines exclusively owned and developed by the Sellers.

~~THC FARMACEUTICALS, INC. BY: ED ROSENTHAL Ed Rosenthal, President~~SIGNATURES

~~-2-~~Pursuant to the requirements of the Securities Exchange Act of 1933, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated this 27^th day of March 2024.

THC FARMACEUTICALS, INC.

BY: /S/ David Tobias

David Tobias, Executive Director

-2-

Filing Compare · THC Farmaceuticals, Inc.